Immunotherapy was again validated as an effective means of fighting cancer and prolonging life when new cancer research results were presented Saturday at the annual meeting of the American Society of Clinical Oncology in Chicago. As reported in the Wall Street Journal, study results were heralded by many of the 30,000 cancer specialists in attendance as “a breakthrough” with the potential to change the direction of mainstream cancer treatment protocols.

Among the more interesting cancer study results were increased survival rates for some of the new immunotherapy drugs either alone or in combination with other drugs. The conference was the first time long-term results were reported for some of the most promising new cancer drugs currently in development.

Immunotherapy treatments are designed to work with the patient’s own immune system, stimulating it to target and destroy cancer cells. Many members of the cancer community believe immunotherapy is revolutionizing the way we treat cancer. A growing history of success indicates that immunotherapy treatment protocols have the potential to significantly improve survival rates in patients with many types of tumors, including often fatal lung and kidney cancer. Of equal importance is growing evidence that immunotherapy can successfully treat advanced stages of cancer.

Immunotherapy cancer treatments are already used extensively in alternative cancer therapy. Our founder, the renowned German cancer specialist Dr. Josef M. Issels, was an early pioneer in the use of immunotherapy to treat cancer. Issels Integrative Oncology Centers have more than 60 years of experience using immunotherapy to successfully treat a wide variety of cancers at all stages of development.